What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Multiple sclerosis
Fred D. Lublin mainly investigates Multiple sclerosis, Internal medicine, Surgery, Expanded Disability Status Scale and Randomized controlled trial.
His Multiple sclerosis study combines topics from a wide range of disciplines, such as Clinical trial, Central nervous system disease and MEDLINE.
His Internal medicine research is multidisciplinary, relying on both Gastroenterology, Placebo and Placebo-controlled study.
His research integrates issues of Glatiramer acetate, Neurology and Pediatrics in his study of Surgery.
His Expanded Disability Status Scale course of study focuses on Peripheral edema and myalgia, Pulmonary embolism and Laquinimod.
His Multiple sclerosis functional composite research is multidisciplinary, incorporating elements of Poser criteria, McDonald criteria, Chronic cerebrospinal venous insufficiency, Medical physics and Clinically isolated syndrome.
His most cited work include:
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria (7085 citations)
- Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis (5753 citations)
- Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". (4139 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Multiple sclerosis, Internal medicine, Immunology, In patient and Natalizumab.
His study of Expanded Disability Status Scale is a part of Multiple sclerosis.
His specific area of interest is Expanded Disability Status Scale, where Fred D. Lublin studies Multiple sclerosis functional composite.
He has included themes like Gastroenterology, Placebo, Interferon beta-1a and Oncology in his Internal medicine study.
The study incorporates disciplines such as Fingolimod and Adverse effect in addition to Placebo.
His research investigates the link between Clinical trial and topics such as Disease that cross with problems in Intensive care medicine.
He most often published in these fields:
- Multiple sclerosis (60.16%)
- Internal medicine (27.81%)
- Immunology (14.17%)
What were the highlights of his more recent work (between 2016-2021)?
- Multiple sclerosis (60.16%)
- Internal medicine (27.81%)
- In patient (14.17%)
In recent papers he was focusing on the following fields of study:
Fred D. Lublin mainly focuses on Multiple sclerosis, Internal medicine, In patient, Magnetic resonance imaging and Expanded Disability Status Scale.
His studies in Multiple sclerosis integrate themes in fields like White matter, MEDLINE, Ocrelizumab, Disease and Cohort.
Fred D. Lublin works mostly in the field of Internal medicine, limiting it down to topics relating to Interferon beta-1a and, in certain cases, Gastroenterology, as a part of the same area of interest.
His studies deal with areas such as Placebo, Teriflunomide, Pediatrics and Neuromyelitis optica as well as Expanded Disability Status Scale.
His Randomized controlled trial research incorporates themes from Observational study, Glatiramer acetate, Clinical trial and Physical therapy.
His Hazard ratio study combines topics in areas such as Siponimod, Proportional hazards model, Surgery, Intention-to-treat analysis and Multicenter trial.
Between 2016 and 2021, his most popular works were:
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (1618 citations)
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis (720 citations)
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. (670 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Multiple sclerosis
His primary areas of study are Multiple sclerosis, Internal medicine, Clinical endpoint, Hazard ratio and Expanded Disability Status Scale.
Fred D. Lublin interconnects Clinical course, MEDLINE, Disease course, Magnetic resonance imaging and Neuroscience in the investigation of issues within Multiple sclerosis.
His research in Internal medicine focuses on subjects like T2 lesions, which are connected to Disability progression, Disease activity, Lesion, Cardiology and Lesion volume.
His Clinical endpoint research focuses on Placebo and how it relates to Adverse effect, Odds ratio, Concomitant, Surgery and Intention-to-treat analysis.
His Expanded Disability Status Scale research integrates issues from Tolerability, Cetirizine and Neuromyelitis optica.
His study looks at the intersection of Clinically isolated syndrome and topics like ON - Optic nerve with Intensive care medicine.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
